Bavcar S, Argyle DJ: Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. Vet Comp Oncol. 2012, 10 (3): 163-173.
Article
CAS
PubMed
Google Scholar
Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol. 2002, 39 (5): 529-535.
Article
CAS
PubMed
Google Scholar
Webster JD, Kiupel M, Kaneene JB, Miller R, Yuzbasiyan-Gurkan V: The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol. 2004, 41 (4): 371-377.
Article
PubMed
Google Scholar
London CA, Galli SJ, Yuuki T, Hu ZQ, Helfand SC, Geissler EN: Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol. 1999, 27 (4): 689-697.
Article
CAS
PubMed
Google Scholar
London CA, Thamm DH: Mast cell tumors. Small Animal Clinical Oncology. Edited by: Withrow SJ, Vail DM, Page RL. 2013, St. Louis: Elsevier Saunders, 335-355. 5
Chapter
Google Scholar
Downing S, Chien MB, Kass PH, Moore PE, London CA: Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res. 2002, 63 (12): 1718-1723.
Article
CAS
PubMed
Google Scholar
Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M: The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia. 2006, 8 (2): 104-111.
Article
PubMed Central
CAS
PubMed
Google Scholar
Letard S, Yang Y, Hanssens K, Palmerini F, Leventhal PS, Guery S, Moussy A, Kinet JP, Hermine O, Dubreuil P: Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res. 2008, 6 (7): 1137-1145.
Article
CAS
PubMed
Google Scholar
Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA: Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res. 2003, 9 (15): 5729-5734.
CAS
PubMed
Google Scholar
Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, Hamilton E, Kiupel M: Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res. 2008, 4: 32.
Article
PubMed Central
PubMed
Google Scholar
Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH: Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. J Vet Intern Med. 2012, 26 (1): 135-141.
Article
CAS
PubMed
Google Scholar
Avery AC: Molecular diagnostics of hematologic malignancies in small animals. Vet Clin North Am Small Anim Pract. 2012, 42 (1): 97-110.
Article
PubMed
Google Scholar
London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM: Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009, 15 (11): 3856-3865.
Article
CAS
PubMed
Google Scholar
Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman I, Vail DM: Safety evaluation of combination vinblastine and toceranib phosphate (Palladia(R)) in dogs: a phase I dose-finding study. Vet Comp Oncol. 2012, 10 (3): 174-183.
Article
CAS
PubMed
Google Scholar
Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Picki WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P: Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol. 2007, 35 (10): 1510-1521.
Article
CAS
PubMed
Google Scholar
London CA, Seguin B: Mast cell tumors in the dog. Vet Clin N Am Small Anim Pract. 2003, 33 (3): 473-489.
Article
Google Scholar
Roskoski R: Signaling by Kit protein-tyrosine kinase–the stem cell factor receptor. Biochem Biophys Res Commun. 2005, 337 (1): 1-13.
Article
CAS
PubMed
Google Scholar
Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007, 6 (9): 734-745.
Article
CAS
PubMed
Google Scholar
Yancey MF, Merritt DA, Lesman SP, Boucher JF, Michels GM: Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. J Vet Pharmacol Ther. 2010, 33 (2): 162-171.
Article
CAS
PubMed
Google Scholar
Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA: Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013, 9: 190.
Article
PubMed Central
PubMed
Google Scholar
Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008, 22 (6): 1301-1309.
Article
CAS
PubMed
Google Scholar
Garraway LA, Janne PA: Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012, 2 (3): 214-226.
Article
CAS
PubMed
Google Scholar
Nguyen KS, Kobayashi S, Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009, 10 (4): 281-289.
Article
PubMed Central
CAS
PubMed
Google Scholar
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2 (3): e73.
Article
PubMed Central
PubMed
Google Scholar
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006, 24 (29): 4764-4774.
Article
CAS
PubMed
Google Scholar
Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S: Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci. 2008, 99 (4): 799-804.
Article
CAS
PubMed
Google Scholar
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008, 26 (33): 5352-5359.
Article
PubMed Central
CAS
PubMed
Google Scholar
Engelman JA, Janne PA: Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008, 14 (10): 2895-2899.
Article
PubMed
Google Scholar
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhai JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegal R, Wargo JA, Hahn WC, Garrawy LA: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010, 468 (7326): 968-972.
Article
PubMed Central
CAS
PubMed
Google Scholar
Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Janne PA, Engelman JA: Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011, 71 (3): 1081-1091.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Janne PA: Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012, 2 (10): 934-947.
Article
PubMed Central
CAS
PubMed
Google Scholar
Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, Kanda N, Sekikawa A, Fukui H, Yanagita M, Yoshibayashi H, Satoh S, Sakai Y, Nakano T, Chiba T: Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog. 2007, 46 (2): 155-164.
Article
CAS
PubMed
Google Scholar
Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, Nagle R, Bearss D: A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007, 26 (27): 3909-3919.
Article
CAS
PubMed
Google Scholar
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010, 468 (7326): 973-977.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011, 29 (22): 3085-3096.
Article
PubMed Central
CAS
PubMed
Google Scholar
Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA: Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008, 216 (1): 64-74.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gramza AW, Corless CL, Heinrich MC: Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009, 15 (24): 7510-7518.
Article
CAS
PubMed
Google Scholar
Engelman JA, Settleman J: Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev. 2008, 18 (1): 73-79.
Article
CAS
PubMed
Google Scholar
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006, 103 (7): 2316-2321.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293 (5531): 876-880.
Article
CAS
PubMed
Google Scholar
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Janne PA: Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene. 2010, 29 (16): 2346-2356.
Article
PubMed Central
CAS
PubMed
Google Scholar
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007, 104 (52): 20932-20937.
Article
PubMed Central
CAS
PubMed
Google Scholar
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007, 316 (5827): 1039-1043.
Article
CAS
PubMed
Google Scholar
Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005, 128 (2): 270-279.
Article
CAS
PubMed
Google Scholar
Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV: MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003, 101 (6): 2368-2373.
Article
CAS
PubMed
Google Scholar
Nakaichi M, Takeshita Y, Okuda M, Nakamoto Y, Itamoto K, Une S, Sasaki N, Kadosawa T, Takahashi T, Taura Y: Expression of the MDR1 gene and P-glycoprotein in canine mast cell tumor cell lines. J Vet Med Sci. 2007, 69 (2): 111-115.
Article
CAS
PubMed
Google Scholar
Shukla S, Robey RW, Bates SE, Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009, 37 (2): 359-365.
Article
PubMed Central
CAS
PubMed
Google Scholar
DeVinney R, Gold WM: Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol. 1990, 3 (5): 413-420.
Article
CAS
PubMed
Google Scholar
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25 (4): 402-408.
Article
CAS
PubMed
Google Scholar
Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol. 1994, 46 (4): 627-638.
CAS
PubMed
Google Scholar
Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG: Tumor P-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer. Front Pharmacol. 2013, 4: 22.
Article
PubMed Central
PubMed
Google Scholar